. 2018 Feb 26;178(5):491–499. doi: 10.1530/EJE-17-1073
This work is licensed under a Table 1.
Baseline characteristics.
| Somapacitan once-weekly (n = 61) | Norditropin once-daily (n = 31) | |
|---|---|---|
| Age (years), mean (s.d.) | 48.1 (16.2) | 51.7 (17.1) |
| Female, n (%) | 28 (45.9) | 14 (45.2) |
| Race, n (%) | ||
| Asian | 12 (19.7) | 6 (19.4) |
| White | 36 (59.0) | 18 (58.1) |
| Not available | 13 (21.3) | 7 (22.6) |
| Body weight (kg), mean (s.d.) | 82.1 (17.6) | 81.0 (21.8) |
| BMI (kg/m2), mean (s.d.) | 28.6 (5.0) | 28.5 (5.6) |
| GHD onset, n (%) | ||
| Childhood – idiopathic | 6 (9.8) | 3 (9.7) |
| Childhood – organic | 18 (29.5) | 7 (22.6) |
| Adulthood | 37 (60.7) | 21 (67.7) |
| IGF-I SDS | 0.28 (1.50) | 0.91 (1.24) |
| GH dose level at screening (mg), mean (s.d.) | 0.5 (0.3) | 0.5 (0.9) |
BMI, body mass index; GH, grouwth hormone; GHD, growth hormone deficiency; SDS, standard deviation score.